Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of myeloid-derived suppressor cells in cancer immunotherapy

International Journal of Cancer

Volumn 128, Issue 1, 2011, Pages 119-131

  Ohkusu Tsukada, Kozo ^a,b   Ohta, Shigeki ^a   Kawakami, Yutaka ^a   Toda, Masahiro ^a  

^a KEIO UNIVERSITY   (Japan)

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

B cells; HSV; Myeloid derived suppressor cells (MDSCs)

Indexed keywords

FORMALDEHYDE; FORMALIN INACTIVATED HSV; NEUROPILIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL EXPANSION; CELL SECRETION; CONTROLLED STUDY; CROSS PRESENTATION; FEMALE; HERPES SIMPLEX VIRUS 1; MOUSE; MYELOID DENDRITIC CELL; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SUPPRESSOR CELL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; VIRUS PURIFICATION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; FORMALDEHYDE; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 9; VACCINES, INACTIVATED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VERO CELLS;

EID: 78349285473     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25319     Document Type: Article

References (50)

1. Pashine A, Valiante NM, Ulmer JB,. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11: S63 8.
2. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V, Palucka AK, Banchereau J,. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219: 118 42.
3. Iwasaki A,., Medzhitov R,. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987 95.
4. Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, Arnold MM, Knipe DM, Finberg RW,. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA 2004; 101: 1315 20.
5. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M,. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004; 103: 1433 37.
6. Reske A, Pollara G, Krummenacher C, Katz DR, Chain BM,. Glycoprotein-dependent and TLR2-independent innate immune recognition of herpes simplex virus-1 by dendritic cells. J Immunol 2008; 180: 7525 36.
7. Menotti L, Avitabile E, Dubreuil P, Lopez M, Campadelli-Fiume G,. Comparison of murine and human nectin1 binding to herpes simplex virus glycoprotein D (gD) reveals a weak interaction of murine nectin1 to gD and a gD-dependent pathway of entry. Virology 2001; 282: 256 66.
8. Montgomery RI, Warner MS, Lum BJ, Spear PG,. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427 36.
9. Pollara G, Jones M, Handley ME, Rajpopat M, Kwan A, Coffin RS, Foster G, Chain B, Katz DR,. Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type I IFN secretion. J Immunol 2004; 173: 4108 19.
10. Satoh T, Arii J, Suenaga T, Wang J, Kogure A, Uehori J, Arase N, Shiratori I, Tanaka S, Kawaguchi Y, Spear PG, Lanier LL, Arase H,. PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 2008; 132: 935 44.
11. Shiratori I, Ogasawara K, Saito T, Lanier LL, Arase H,. Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor. J Exp Med 2004; 199: 525 33.
12. Eloranta ML, Alm GV,. Splenic marginal metallophilic macrophages and marginal zone macrophages are the major interferon-α/β producers in mice upon intravenous challenge with herpes simplex virus. Scand J Immunol 1999; 49: 391 4.
13. Riffault S, Carrat C, Milon G, Charley B, Colle JH,. Transient IFN-? synthesis in the lymph node draining a dermal site loaded with UV-irradiated herpes simplex virus type 1: an NK- and CD3-dependent process regulated by IL-12 but not by IFN-α/β. J Gen Virol 2000; 81: 2365 73.
14. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A,. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513 20.
15. Serafini P, Borrello I, Bronte V,. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53 65.
16. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S,. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67: 10019 26.
17. 2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507 13.
18. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA,. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741 52.
19. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna GJ,. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181: 4666 75.
20. Kusmartsev SA, Li Y, Chen SH,. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165: 779 85.
21. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB,. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003; 170: 5064 74.
22. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI,. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989 99.
23. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI,. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828 35.
24. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC,. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64: 5839 49.
25. Rodriguez PC, Quiceno DG, Ochoa AC,. L -arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109: 1568 73.
26. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M,. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735 45.
27. Otrock ZK, Makarem JA, Shamseddine AI,. Vascular endothelial growth factor family of ligands and receptors. Blood Cells Mol Dis 2007; 38: 258 68.
28. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP,. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624 31.
29. Larrivée B, Pollet I, Karsan A,. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol 2005; 175: 3015 24.
30. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M,. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci USA 2000; 97: 2573 78.
31. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, Wu MH, Yang SC, Pan SH, Shih JY, Chan WK, Yang PC,. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 2007; 13: 4759 68.
32. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S,. Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740 5.
33. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR,. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17 27.
34. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P,. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270 8.
35. Kim WU, Kang SS, Yoo SA, Hong KH, Bae DG, Lee MS, Hong SW, Chae CB, Cho CS,. Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. J Immunol 2006; 177: 5727 35.
36. den Haan JM, Lehar SM, Bevan MJ,. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685 96.
37. Chhabra A, Mehrotra S, Chakraborty NG, Mukherji B, Dorsky DI,. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur J Immunol 2004; 34: 2824 33.
38. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D,. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411 5.
39. Huard B, Fruh K,. A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur J Immunol 2000; 30: 509 15.
40. Jerome KR, Fox R, Chen Z, Sears AE, Lee H, Corey L,. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol 1999; 73: 8950 7.
41. De Visser KE, Korets LV, Coussens LM,. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411 23.
42. Qin Z, Richter G, Schler T, Ibe S, Cao X, Blankenstein T,. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4: 627 30.
43. Yamada Y, Oike Y, Ogawa H, Ito Y, Fujisawa H, Suda T, Takakura N,. Neuropilin-1 on hematopoietic cells as a source of vascular development. Blood 2003; 101: 1801 9.
44. Yamada Y, Takakura N, Yasue H, Ogawa H, Fujisawa H, Suda T,. Exogenous clustered neuropilin 1 enhances vasculogenesis and angiogenesis. Blood 2001; 97: 1671 8.
45. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL,. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867 74.
46. Iizuka Y, Suzuki A, Kawakami Y, Toda M,. Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12. J Immunother 2004; 27: 92 8.
47. Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y,. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 2002; 9: 356 64.
48. Toda M, Martuza RL, Rabkin SD,. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther 2001; 8: 332 9.
49. Toda M, Martuza RL, Kojima H, Rabkin SD,. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457 64.
50. Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ,. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep Part 3 1972; 3: 1 103.